BOSTON MEDICAL CENTER CORPORATION
- Type
- Non-covered entity
- Where
- SOUTH BOSTON, MA
- Received
- $739,068 in 23 records, 2021 to 2025 ($0 general, $739,068 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Boston Medical Center Corporation Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Nonprofit contractor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Patent assignee: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Trademark owner: Boston Medical Center Corporation Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | Research payment | 8 | $7,147 |
| 2024 | Research payment | 11 | $700,527 |
| 2023 | Research payment | 2 | $18,141 |
| 2021 | Research payment | 2 | $13,252 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 4 | $617,953 | 2024 |
| Novartis Pharmaceuticals Corporation | 4 | $83,886 | 2023–2024 |
| Inari Medical, Inc. | 4 | $15,528 | 2024 |
| Neurocrine BioSciences, Inc. | 2 | $13,252 | 2021 |
| GlaxoSmithKline, LLC. | 7 | $6,985 | 2025 |
| Alexion Pharmaceuticals, Inc. | 1 | $1,300 | 2023 |
| ViiV Healthcare Company | 1 | $162 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 23 | $739,068 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-07-21 | GlaxoSmithKline, LLC. | $550 | Research payment | Cash or cash equivalent | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | 2025 | |
| 2025-05-02 | GlaxoSmithKline, LLC. | $2,730 | Research payment | Cash or cash equivalent | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | 2025 | |
| 2025-03-21 | GlaxoSmithKline, LLC. | $1,300 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | 2025 | |
| 2025-03-21 | GlaxoSmithKline, LLC. | $1,300 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | 2025 | |
| 2025-03-21 | GlaxoSmithKline, LLC. | $812 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | 2025 | |
| 2025-03-21 | GlaxoSmithKline, LLC. | $130 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | 2025 | |
| 2025-02-07 | ViiV Healthcare Company | $162 | Research payment | Cash or cash equivalent | A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E | 2025 | |
| 2025-02-03 | GlaxoSmithKline, LLC. | $162 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | 2025 | |
| 2024-12-17 | Novartis Pharmaceuticals Corporation | $29,041 | Research payment | Cash or cash equivalent | A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safet | 2024 | |
| 2024-10-21 | Merck Sharp & Dohme LLC | $232,883 | Research payment | Cash or cash equivalent | PNEUMOVAX 23 Biological, VACCINE | Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients | 2024 |
| 2024-10-21 | Merck Sharp & Dohme LLC | $95,699 | Research payment | Cash or cash equivalent | STUDY NAME#Addressing disparities in influenza vaccination# Develop and pilot test a novel methodology grounded in the C | 2024 | |
| 2024-08-19 | Inari Medical, Inc. | $3,055 | Research payment | Cash or cash equivalent | LIMFLOW SYSTEM Device, CLTI | PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia | 2024 |
| 2024-08-19 | Inari Medical, Inc. | $3,055 | Research payment | Cash or cash equivalent | LIMFLOW SYSTEM Device, CLTI | PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia | 2024 |
| 2024-08-05 | Merck Sharp & Dohme LLC | $201,519 | Research payment | Cash or cash equivalent | GARDASIL 9 Biological, VACCINE | An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination 2-dose Regimen over a Fo | 2024 |
| 2024-07-16 | Novartis Pharmaceuticals Corporation | $27,303 | Research payment | Cash or cash equivalent | Fabhalta Drug, Immunology | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of | 2024 |
| 2024-04-24 | Inari Medical, Inc. | $8,043 | Research payment | Cash or cash equivalent | LIMFLOW SYSTEM Device, CLTI | PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia | 2024 |
| 2024-04-23 | Inari Medical, Inc. | $1,375 | Research payment | Cash or cash equivalent | LIMFLOW SYSTEM Device, CLTI | PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia | 2024 |
| 2024-03-12 | Novartis Pharmaceuticals Corporation | $10,699 | Research payment | Cash or cash equivalent | ADAKVEO Drug, Hematology | A phase III, Multicenter, Randomized, Placebo controlled, Double-blind Study to Assess Efficacy and Safety of Two Doses | 2024 |
| 2024-03-04 | Merck Sharp & Dohme LLC | $87,850 | Research payment | Cash or cash equivalent | STUDY NAME#Molecular characterization of virulence factors in an in vitro model of Respiratory Synctial Virus and Strept | 2024 | |
| 2023-11-29 | Alexion Pharmaceuticals, Inc. | $1,300 | Research payment | Cash or cash equivalent | A Phase 2a, Randomized, Open Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Patients | 2023 | |
| 2023-03-13 | Novartis Pharmaceuticals Corporation | $16,841 | Research payment | Cash or cash equivalent | ADAKVEO Drug, Hematology | A phase III, Multicenter, Randomized, Placebo controlled, Double-blind Study to Assess Efficacy and Safety of Two Doses | 2023 |
| 2021-07-16 | Neurocrine BioSciences, Inc. | $10,825 | Research payment | Cash or cash equivalent | OPEN-LABEL ROLLOVER STUDY FOR CONTINUING VALBENAZINE ADMINISTRATION FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGT | 2021 | |
| 2021-07-16 | Neurocrine BioSciences, Inc. | $2,427 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VALBEN | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
In Massachusetts; placed by its state only.
| Measure | State Massachusetts |
|---|---|
| Population B01003 | 7,044,056 |
| Population, 2020 census P1 | 7,029,917 |
| Median age B01002 | 40.0 |
| Under 18 B01001 | 19.4% |
| 65 and over B01001 | 17.9% |
| Households B11001 | 2,785,042 |
| Foreign born B05002 | 18.0% |
| Median household income B19013 | $103,960 |
| Median family income B19113 | $131,675 |
| Per capita income B19301 | $57,897 |
| Poverty rate B17001 | 10.0% |
| Unemployment rate B23025 | 5.2% |
| Civilian labor force B23025 | 3,911,446 |
| Mean commute (minutes) B08013 | 29.1 |
| Bachelor's degree or higher B15003 | 47.3% |
| Housing units B25001 | 3,030,406 |
| Owner-occupied B25003 | 62.5% |
| Renters B25003 | 37.5% |
| Median home value B25077 | $562,100 |
| Median gross rent B25064 | $1,762 |
| White, not Hispanic B03002 | 66.6% |
| Black B03002 | 6.4% |
| Hispanic or Latino B03002 | 13.3% |
| Asian B03002 | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Massachusetts.
Comments